Sangui Biotech International (Sangui Biotech International) EV-to-EBIT : -10.88 (As of Apr. 25, 2024)

Sangui Biotech International EV-to-EBIT Chart

Sangui Biotech International Annual Data
	Trend	Jun13	Jun14	Jun15	Jun16	Jun17	Jun18	Jun19	Jun20	Jun21	Jun22
EV-to-EBIT		Get a 7-Day Free Trial					-16.61	-5.45	-16.14	-25.33	-50.86

Sangui Biotech International Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
EV-to-EBIT	Get a 7-Day Free Trial															-47.54	-50.86	251.69	-13.15	-10.83

Competitive Comparison of Sangui Biotech International's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Sangui Biotech International's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sangui Biotech International's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sangui Biotech International's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Sangui Biotech International's EV-to-EBIT falls into.

Sangui Biotech International EV-to-EBIT Calculation

Sangui Biotech International's EV-to-EBIT for today is calculated as:

Sangui Biotech International's current Enterprise Value is $1.14 Mil.
Sangui Biotech International's EBIT for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.11 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sangui Biotech International  (OTCPK:SGBI) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Sangui Biotech International's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2023 is calculated as:

Sangui Biotech International's Enterprise Value for the quarter that ended in Mar. 2023 was $1.14 Mil.
Sangui Biotech International's EBIT for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.11 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sangui Biotech International EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Sangui Biotech International's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Sangui Biotech International (Sangui Biotech International) Business Description